Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Strong Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Blueprint Medicines Corporation (BPMC)

Pharmaceutical Preparations

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

45 SIDNEY STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/30/2015

Market Cap

5,987,416,660

Shares Outstanding

60,790,000

Weighted SO

60,789,712

Total Employees

N/A

Upcoming Earnings

10/24/2024

Similar Tickers

TERN --.--%

AMLX --.--%

ABOS --.--%

INZY --.--%

XFOR --.--%

PTCT --.--%

KRYS --.--%

ICPT --.--%

MDGL --.--%

Beta

0.6310

Last Div

0.0000

Range

43.89-121.9

Chg

-1.0000

Avg Vol

682183

Mkt Cap

5987416660

Exch

NASDAQ

Country

US

Phone

617 374 7580

DCF Diff

0.8421

DCF

46.9379

Div Yield

0.0000

P/S

16.5035

EV Multiple

-19.2861

P/FV

18.5515

Div Yield %

0.0000

P/E

-28.9113

PEG

-1.9865

Payout

0.0000

Current Ratio

3.7060

Quick Ratio

3.6454

Cash Ratio

0.2247

DSO

85.5747

DIO

211.2301

Op Cycle

296.8048

DPO

69.3864

CCC

227.4184

Gross Margin

0.9296

Op Margin

-0.9812

Pretax Margin

-0.5649

Net Margin

-0.5664

Eff Tax Rate

-0.0026

ROA

-0.1707

ROE

-0.8525

ROCE

-0.3709

NI/EBT

1.0026

EBT/EBIT

0.5758

EBIT/Rev

-0.9812

Debt Ratio

0.5526

D/E

2.0769

LT Debt/Cap

0.6322

Total Debt/Cap

0.6750

Int Coverage

-18.3436

CF/Debt

-0.5007

Equity Multi

3.7583

Rec Turnover

4.2653

Pay Turnover

5.2604

Inv Turnover

1.7280

FA Turnover

3.3269

Asset Turnover

0.3014

OCF/Share

-5.2979

FCF/Share

-5.5302

Cash/Share

12.1488

OCF/Sales

-0.9179

FCF/OCF

1.0438

CF Coverage

-0.5007

ST Coverage

-2.9043

CapEx Coverage

-22.8126

Div&CapEx Cov

-22.8126

P/BV

18.5515

P/B

18.5515

P/S

16.5035

P/E

-28.9113

P/FCF

-17.2254

P/OCF

-17.8409

P/CF

-17.8409

PEG

-1.9865

P/S

16.5035

EV Multiple

-19.2861

P/FV

18.5515

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 15, 19:51 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders GlobeNewswire Inc. Jun 15, 17:53 HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V. (NASDAQ: ATAI) Benzinga Jan 09, 10:00 Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say MarketWatch Dec 23, 06:50 Biotech stocks set for a rebound in 2024, analysts say Benzinga Dec 22, 12:00 Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know MarketWatch Dec 22, 11:06 Biotech stocks set for a rebound in 2024, analysts say Benzinga Oct 27, 13:00 Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know Benzinga Oct 27, 13:00 Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know The Motley Fool Oct 26, 17:47 Why Blueprint Medicines Stock Soared Today

Revenue Product Segmentation